Abstract
Objectives The identification of novel uses for existing drug therapies has the potential to provide a rapid, low-cost approach to drug (re)discovery. In the current study we developed and tested a genetically-informed drug-repurposing pipeline for diabetes management.
Design We developed and tested a genetically-informed drug-repurposing pipeline for diabetes management. This approach mapped genetically predicted gene expression signals from the largest genome-wide association study for type 2 diabetes mellitus to drug targets using publicly available databases to identify drug-gene pairs. These drug-gene pairs were then validated using a two-step approach: 1) a self-controlled case-series (SCCS) using electronic health records from a discovery and replication population, and 2) Mendelian randomization (MR).
Setting The SCCS experiments were completed using two EHRs: the Million Veterans Program (USA) as the discovery and the Vanderbilt University Medical Center (Tennessee, USA) as the replication.
Results After filtering on sample size, 20 candidate drug-gene pairs were validated and various medications demonstrated evidence of glycemic regulation including two anti-hypertensive classes: angiotensin-converting enzyme inhibitors as well as calcium channel blockers (CCBs). The CCBs demonstrated the strongest evidence of glycemic reduction in both validation approaches (SCCS HbA1c and glucose reduction: -0.11%, p=0.01 and -0.85 mg/dL, p=0.02, respectively; MR: OR=0.84, 95% CI=0.81, 0.87, p=5.0×10-25).
Conclusions Our results support CCBs as a strong candidate medication for blood glucose reduction in addition to cardiovascular disease reduction. Further, these results support the adaptation of this approach for use in future drug-repurposing efforts for other conditions.
Section 1: What is already known on this topic Medications with genetic support are significantly more likely to make it through clinical trials.
Section 2: What this study adds Our results identified two anti-hypertensive medication classes, calcium channel blockers and angiotensin-converting enzyme inhibitors, as genetically supported drug-repurposing targets that demonstrated glycemic measurement reduction in real-world clinical populations. These results suggest patients with diabetes or pre-diabetes could benefit from preferential use of these medication classes when they present with comorbid hypertension or other cardiovascular conditions. Finally, this study demonstrates a successful implementation of a novel genetically-supported drug-repurposing pipeline for diabetes treatment that can be readily adapted and applied to other diseases and as such it has the potential to identify/prioritize drug repurposing targets for these other conditions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The dataset used for the replication analyses was obtained from the Vanderbilt University Medical Center Synthetic Derivative, which is supported by institutional funding, the 1S10RR025141-01 instrumentation award, and by the CTSA grant UL1TR000445 from National Center for Advancing Translational Sciences/National Institutes of Health. M.M.S. was supported by AHA 17SFRN33520017 and VA Merit I01 BX005399-01A1. N.K.K. is supported by NIH R00 CA215360. V.W. is supported by the Medical Research Council Integrative Epidemiology Unit at the University of Bristol, UK [MC_UU_00011/4] and the COVID-19 Longitudinal Health and Wellbeing National Core Study, which is funded by the UK Medical Research Council (MC_PC_20059). M.V. and P.R. are supported by 2I01BX003362-03A1. This work was supported using resources and facilities of the US Department of Veterans Affairs (VA), Veterans Health Administration, Cooperative Studies Program, grant number 825-MS-DI-33848, and used resources and facilities at the VA Informatics and Computing Infrastructure (VINCI), VA HSR RES 13-457.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The studies obtained ethical approval from the affiliated organizations, Department of Veterans Affairs and Vanderbilt University Medical Center, Nashville, TN. For the Vanderbilt University Medical Center Synthetic derivative patient data is de-identified and do not meet the 45 CFR 46 definition for human subjects research. As such, the study received non-human subjects determination from the associated institutional review board. For the Department of Veterans Affairs dataset the study was reviewed and approved by institutional review boards and research committees at 3 VA Medical Centers (Salt Lake City, Palo Alto, and West Haven) with approved waivers of informed consent and HIPAA authorization.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Copyright The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive license (or non-exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd to permit this article (if accepted) to be published in BMJ editions and any other BMJPGL products and sublicences such use and exploit all subsidiary rights, as set out in our license.
Ethics Approval The studies obtained ethical approval from the affiliated organizations, Department of Veterans Affairs and Vanderbilt University Medical Center. For the Vanderbilt University Medical Center Synthetic derivative patient data is de-identified and do not meet the 45 CFR 46 definition for human subjects research. As such, the study received non-human subjects determination from the associated institutional review board.
Transparency Statement The corresponding authors affirm that the manuscript is an honest, accurate and transparent account of the reported study. No important aspects of the study have been omitted and all discrepancies from the study have been explained.
Conflicts of Interest No conflicts of interest
Funding Sources The dataset used for the replication analyses was obtained from the Vanderbilt University Medical Center Synthetic Derivative, which is supported by institutional funding, the 1S10RR025141-01 instrumentation award, and by the CTSA grant UL1TR000445 from National Center for Advancing Translational Sciences/National Institutes of Health. M.M.S. was supported by AHA 17SFRN33520017 and VA Merit I01 BX005399-01A1. N.K.K. is supported by NIH R00 CA215360. V.W. is supported by the Medical Research Council Integrative Epidemiology Unit at the University of Bristol, UK [MC_UU_00011/4] and the COVID-19 Longitudinal Health and Wellbeing National Core Study, which is funded by the UK Medical Research Council (MC_PC_20059). M.V. and P.R. are supported by 2I01BX003362-03A1. This work was supported using resources and facilities of the US Department of Veterans Affairs (VA), Veterans Health Administration, Cooperative Studies Program, grant number 825-MS-DI-33848, and used resources and facilities at the VA Informatics and Computing Infrastructure (VINCI), VA HSR RES 13-457.
Data Sharing Summary level statistical results will be made available upon reasonable request to corresponding authors. Individual level data can be made available following institutional agreements.
Data Availability
Summary level statistical results will be made available upon reasonable request to corresponding authors. Individual level data can be made available following institutional agreements.
